Kevin Eisele, managing director, healthcare equity capital markets for William Blair, was quoted in the Wall Street Journal’s Venture Capital Pro where he discussed the firm’s quarterly biopharma report findings and the current landscape for smaller-cap biopharma companies, the potential for IPOs in the sector, and more.
Eisele told the publication that the industry has reached a stage where many smaller biopharma companies now have approvals for their drugs and more cash on-hand that could place them in the M&A market in the coming years.